Insights Across the
Access Ecosystem

Patients can receive coverage approval and still face delays before starting therapy. Connected pharmacy coordination helps bring prescription routing, affordability, dispensing, fulfillment, and delivery into the broader patient access strategy.

A patient can have coverage and still be unable to start therapy. This blog explains why affordability support should be built into the case workflow, pharmacy coordination, reporting, and broader patient access strategy.

Approval alone does not guarantee access. Signal 4 explores why manufacturers need to pressure-test pull-through strategy, coding, billing, PA requirements, provider workflow, and payer friction before operational barriers slow patient starts.

Point solutions can bring meaningful innovation to patient services, but only if they connect into a broader operating infrastructure. This blog explores why modern patient services technology needs a source of truth that helps workflows, partners, data, and support teams work together across the patient journey.

Approval alone does not guarantee access. Signal 4 explores why manufacturers need to pressure-test pull-through strategy, coding, billing, PA requirements, provider workflow, and payer friction before operational barriers slow patient starts.

Formulary pressure does not always appear as a sudden access loss. Signal 3 explores why manufacturers need to pressure-test payer expectations, utilization management risk, and clinical differentiation before quiet restrictions become real access barriers.

Patient services models are often described as outsourced, hybrid, or insourced, but structure is only part of the decision. This blog explores what modern patient services models need to support, from reimbursement and affordability to provider visibility, reporting, compliance, and long-term scalability.

Biosimilar and generic entry can reset more than product economics. Signal 2 explores why LOE planning needs earlier payer validation, evidence strategy, and access scenario planning.

For many pharmaceutical and biotech teams, the patient services model decision used to feel relatively straightforward. Outsource the hub. Build internally. Or find a partner to manage the work. Today, that decision is more complicated. For pharma and biotech teams, patient services infrastructure is what determines whether a hub model can support access, affordability, reporting, and long-term scalability. Manufacturers are launching into an access environment shaped by medi

Market access planning is entering a new cycle. Pricing pressure, evidence expectations, contracting strategy, and stakeholder engagement are becoming more connected, and manufacturers can no longer assume that yesterday’s launch playbook will hold up in 2026.

Cash/DTC pharmacy pathways can improve convenience, but they still require prescription management, reporting, visibility, and alignment with the broader access strategy.

CMS’ proposed drug prior authorization reforms signal progress toward faster, more electronic processes. But for manufacturers, the bigger question is whether patient support programs are ready to reduce provider workflow friction and make access easier to navigate.

Modern patient support programs cannot rely on disconnected systems, manual handoffs, and fragmented reporting. Scalable hub models require connected infrastructure, real-time visibility, and workflows that support patients, providers, field teams, and manufacturers.

Pharmaceutical manufacturers are rethinking how access programs are designed, supported, and scaled. For years, pharmacy operations were often treated as a downstream execution step. Once the access strategy was defined, the pharmacy model followed. But today’s patient support environment is more complex. Manufacturers are balancing affordability pressure, specialty pharmacy coordination, hub model evolution, faster therapy initiation, and growing expectations for visibility

Business development decisions are too important to be separated from market access reality. As access dynamics become more complex, BD teams need earlier, faster, and more actionable insight into how the market may respond. Market access should not be treated as a downstream planning function. It should be part of the asset evaluation process from the beginning. Because the value of an asset is not only defined by what it can do clinically. It is also defined by whe

Many Patient Support Programs are designed around ideal processes rather than real-world execution. In this article, we explore why clinician- and operator-informed design creates more resilient PSPs — and how tech-enabled infrastructure like HealthPACER® supports workflows as they actually happen.

In 2026, Field Reimbursement Managers need more than static reports. They need real-time, territory-aware visibility that helps them remove access barriers earlier. Here’s why retrospective dashboards no longer support modern field strategy.

Real-world evidence has long relied on administrative claims datasets. But claims show utilization, not always clinical reasoning. Here’s why pharmaceutical organizations are increasingly adopting EMR-first evidence models to understand treatment decisions, access dynamics, and real-world care.

The first 90 days after launch reveal whether access strategy is performing in clinical reality. Claims data alone shows utilization — not intent. Here’s why EMR-first evidence is becoming essential for decision-grade post-launch validation across pharmaceutical organizations.

Patient Support Programs were once designed as contained environments.Intake came in. Benefits were verified. Prior authorizations were tracked. Financial support was coordinated. Reports were generated.Everything lived inside the hub.But as more manufacturers explore insourced and hybrid hub models, the infrastructure behind patient services is becoming far more complex.In today’s environment, access depends on connection.Prescribing systems evolve. Specialty pharmacy platfo